Patents by Inventor Thong-Gyu JIN

Thong-Gyu JIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treating hunter syndrome
    Patent number: 11052135
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 6, 2021
    Assignees: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATION
    Inventors: Torayuki Okuyama, Thong-Gyu Jin, Han-Yeul Byun, Jin-Wook Seo, Byoung-Ju Lee, Yong-Chul Kim, In-Young Jang, Kyuhyun Lee
  • METHODS AND COMPOSITIONS FOR TREATING HUNTER SYNDROME
    Publication number: 20200268857
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 27, 2020
    Applicants: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Torayuki OKUYAMA, Thong-Gyu JIN, Han-Yeul BYUN, Jin-Wook SEO, Byoung-Ju LEE, Yong-Chul KIM, In-Young JANG, Kyuhyun LEE
  • Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
    Patent number: 10174299
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: January 8, 2019
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20180112199
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.
    Type: Application
    Filed: November 14, 2017
    Publication date: April 26, 2018
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
    Patent number: 9896672
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 20, 2018
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20160326504
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: June 16, 2016
    Publication date: November 10, 2016
    Applicants: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu JIN, Yo Kyung CHUNG, Sang Hoon PAIK, Yoo Chang PARK, Jinwook SEO, Yong Woon CHOI, Jong Mun SON, Yong-Chul KIM
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20160145589
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: December 21, 2015
    Publication date: May 26, 2016
    Applicants: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
    Patent number: 9249397
    Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: February 2, 2016
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
    Patent number: 9206402
    Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: December 8, 2015
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20150320843
    Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: July 27, 2015
    Publication date: November 12, 2015
    Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATION
    Inventors: Thong-Gyu JIN, Yo Kyung CHUNG, Sang Hoon PAIK, Yoo Chang PARK, Jinwook SEO, Yong Woon CHOI, Jong Mun SON, Yong-Chul KIM
  • TRANSGENIC MOUSE MODEL FOR DEVELOPING ENZYME REPLACEMENT THERAPY FOR IDURONATE-2-SULFATASE DEFICIENCY SYNDROME
    Publication number: 20140351964
    Abstract: The present invention relates to a transgenic mouse model for developing enzyme replacement therapy for iduronate-2-sulfatase deficiency syndrome, for example, Hunter syndrome. More specifically, the present invention relates to a transgenic mouse to be used for developing enzyme replacement therapy for iduronate-2-sulfatase, wherein the immune response against injected enzyme, such as, recombinant iduronate-2-sulfatase has been minimized in transgenic mouse model in the course of treating in vivo iduronate-2-sulfatase replacement.
    Type: Application
    Filed: June 3, 2014
    Publication date: November 27, 2014
    Applicant: MEDIGENEBIO CORPORATION
    Inventor: Thong-Gyu Jin
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20140242059
    Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: June 15, 2012
    Publication date: August 28, 2014
    Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATION
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Iduronidase knock-out mouse
    Patent number: 8524976
    Abstract: The present invention relates to a ?-L-iduronidase knock-out mouse. More particularly, this invention relates to a ?-L-iduronidase knock-out mouse to be designed for developing a treatment or an agent for mucopolysaccharidosis type I (Hurler syndrome or Hurler-Scheie syndrome) as an animal model.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: September 3, 2013
    Assignee: Medigenbio Corporation
    Inventor: Thong-Gyu Jin
  • TRANSGENIC MOUSE MODEL FOR DEVELOPING ENZYME REPLACEMENT THERAPY FOR IDURONATE-2-SULFATASE DEFICIENCY SYNDROME
    Publication number: 20120180148
    Abstract: The present invention relates to a transgenic mouse model for developing enzyme replacement therapy for iduronate-2-sulfatase deficiency syndrome, for example, Hunter syndrome. More specifically, the present invention relates to a transgenic mouse to be used for developing enzyme replacement therapy for iduronate-2-sulfatase, wherein the immune response against injected enzyme, such as, recombinant iduronate-2-sulfatase has been minimized in transgenic mouse model in the course of treating in vivo iduronate-2-sulfatase replacement.
    Type: Application
    Filed: January 7, 2011
    Publication date: July 12, 2012
    Inventor: Thong-Gyu JIN
  • Iduronidase knock-out mouse
    Publication number: 20110067120
    Abstract: The present invention relates to a ?-L-iduronidase knock-out mouse. More particularly, this invention relates to a ?-L-iduronidase knock-out mouse to be designed for developing a treatment or an agent for mucopolysaccharidosis type I (Hurler syndrome or Hurler-Scheie syndrome) as an animal model.
    Type: Application
    Filed: September 17, 2009
    Publication date: March 17, 2011
    Inventor: Thong-Gyu JIN